In 1969, a tobacco industry executive wrote an internal memo that would not become public for decades. “Doubt is our product,” it read, “since it is the best means of competing with the body of fact that exists in the minds of the general public.” It was not a confession of wrongdoing, at the time. It was a strategy document. And it worked for thirty years.
The playbook developed by the tobacco industry — fund sympathetic research, dispute the methodology of unfriendly research, cultivate academic credibility through grants and conference sponsorships, and manufacture the impression that the science is unsettled — has since been replicated across industries: sugar, ultra-processed food, alcohol, pharmaceuticals, and others. The mechanisms are now well documented in peer-reviewed literature. The pattern is consistent enough to have a name: the “manufactured uncertainty” industry.
How It Works
The architecture of manufactured uncertainty has four components. First, commission and fund research designed to produce favourable outcomes — not through falsification, but through study design, endpoint selection, and duration choices that tend to minimise apparent harm. Second, flood the academic literature with industry-funded studies, crowding out independent research and making consensus harder to establish. Third, when independent research does find harm, fund rapid response studies that dispute the methodology, and place sympathetic scientists in media to characterise the finding as preliminary and contested. Fourth, engage with regulatory bodies through lobbying, revolving-door relationships, and the strategic provision of funding to the very agencies that regulate the industry.
Each step is legal. Each step is deniable. The cumulative effect is that the public, and often the medical profession, operates with a distorted picture of the evidence for years or decades longer than it should.
What the Documents Show
Internal documents from the tobacco, sugar, and alcohol industries — released through litigation, regulatory action, and investigative journalism — reveal a consistent pattern: awareness of harm preceded public acknowledgment by years or decades. In some cases, internal research confirmed the harms that external researchers were identifying — and that research was suppressed, classified as proprietary, or simply not published.
A 2016 paper in JAMA Internal Medicine revealed that the Sugar Research Foundation funded research in the 1960s that successfully shifted scientific and public attention from sugar to fat as the primary driver of cardiovascular disease — contributing to decades of dietary guidance that may have increased, rather than reduced, metabolic disease rates. The authors of that research did not disclose their funding. The SRF documents had been buried in a researcher’s archive until a historian found them.
What This Means for Investors and Patients
For patients making health decisions, the implication is straightforward: the information reaching the clinical encounter has been filtered through a process that is not neutral. The studies your clinician read in training were not equally likely to have been funded by parties with a financial interest in the outcome. The guidelines written from those studies were not written by committees free of industry relationships.
This is not a counsel of paralysis or paranoia. It is a counsel of calibrated scepticism — the same scepticism a good investor applies to a management team’s projections, or a due diligence team applies to a vendor’s representations. The incentive structure shapes the output. Knowing the incentive structure is part of reading the output correctly.
For investors, the implication runs in both directions. Companies in industries with long histories of manufactured uncertainty face growing liability exposure as documents enter the public record and litigation widens. And industries that have successfully suppressed inconvenient science face eventual reckoning — the tobacco settlements, the opioid settlements, the ongoing alcohol and ultra-processed food litigation — that reshapes the competitive landscape and creates both risk and opportunity.
This article is for educational and informational purposes only. CI Mavericks Advisory Services. Active Advisory. Real Investment. Genuine Expertise.